New whitepaper compares targeted resequencing strategies
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.’ The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods. Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations. OGT has written the whitepaper in response to a growing demand from within its customer base and the NGS community for a balanced and comprehensive guide to targeted resequencing strategies.
Considered from both clinical research and discovery viewpoints, the paper discusses whole exome and targeted panel sequencing strategies, without bias. This includes highlighting the limitations of each approach, and offering advice on when whole genome sequencing is appropriate, providing researchers with insight to identify the most suitable method for the task at hand. Considerations are also presented on choice of capture technologies, bait design and the use of service providers for method optimisation and accessibility to meaningful results.
To learn more about targeted resequencing methods, download the whitepaper.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomics, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.